RxDoctor Payments Data

David Henry, MD

Cardiovascular Disease · Little Rock, ARNPI 1487647806

Payments from drug & device makers

$2,137in general payments, 2019–2025

Across 106 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$708
  • Pfizer$319
  • Johnson & Johnson$277
  • Amgen$253
  • Livanova USA, Inc.$165
  • Abbott$150
  • plus $266 from 6 others

What the payments were for

  • Food & beverage$2,130100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,137 in reported general payments places this provider in the 35th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$339,081
Medicare patients
1,378
Services billed
5,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,089$846,568
EntrestoSacubitril/Valsartan423$354,658
XareltoRivaroxaban335$264,773
JardianceEmpagliflozin296$228,257
MultaqDronedarone Hcl105$123,436
Repatha SureclickEvolocumab91$67,785
FarxigaDapagliflozin Propanediol53$45,940
BrilintaTicagrelor32$23,926
Potassium Chloride821$13,404
Telmisartan570$12,739
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid245$11,063
Rosuvastatin Calcium1,240$10,772
Repatha SyringeEvolocumab12$10,369
Valsartan454$9,598
Torsemide692$6,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$319$846,5681,089 claims
NovartisEntresto$708$354,658423 claims
Johnson & JohnsonXarelto$277$264,773335 claims
Sanofi-aventis U.S. LLCMultaq$128$123,436105 claims
AstraZenecaFarxiga, Brilinta$14$69,86685 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →